Elena Nieto

Elena Nieto

Auto-generated profile, based on publicly available information

Elena Nieto

Department of Hepatology and Liver Transplantation Hospital Virgen de la Candelaria Santa Cruz de Tenerife Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2026 in Liver International
Verified
Journal Article
Open access
Manuel Rodríguez-PerálvarezManuel Rodríguez-Perálvarez
Manuel Rodríguez-Perálvarez
AGAntonio Manuel Gómez-Orellana
Antonio Manuel Gómez-Orellana
AMAvik Majumdar
Avik Majumdar
GMGeoff McCaughan
Geoff McCaughan
Maria KalafateliMaria Kalafateli
Maria Kalafateli
ETEmmanuel Tsochatzis
Emmanuel Tsochatzis
Background and Aims: Although GEMA‐Na outperforms MELD 3.0 for liver allocation, concerns about the subjectivity of its ascites component persist. We compared the performance of a GEMA‐Na iteration that excludes ascites with other allocation scores. Approach and Results: A multinational cohort study was conducted, including adult candidates for elective liver transplantation in the UK (2010–2020), Australia (1998–2020), and Spain (2016–2021). The primary outcome was mortality or delisting for sickness within 90 days. The prognostic impact of ascites was evaluated using multivariable Cox's regression. Discrimination was assessed using Harrell's c‐statistics (Hc). The study included 15 391 patients (28.5% women). The prevalence of the primary outcome was 5.8% in the UK, 5.3% in Australia, and 4.7% in Spain. The presence and severity of ascites was associated with an incremental risk of the primary outcome: 3.3% without ascites, 5.8% with mild ascites, and 7.7% with moderate–severe ascites ( p < 0.001). Removal of ascites from the GEMA‐Na score resulted in a one‐point reduction in 18% of patients (52.4% of patients with moderate–severe ascites). GEMA‐Na without ascites showed only a marginal decrease in discrimination (Hc = 0.755 vs. Hc = 0.753; p = 0.007) but still significantly outperformed MELD 3.0 (Hc = 0.734; p < 0.001) and MELD‐Na (Hc = 0.737; p < 0.001). In women, GEMA‐Na with and without ascites demonstrated comparable discrimination (Hc = 0.784 vs. Hc = 0.783; p = 0.61), both outperforming MELD 3.0 (Hc = 0.750; p < 0.001), and MELD‐Na (Hc = 0.749; p < 0.001). Conclusions: Despite the prognostic impact of ascites among liver transplant candidates, GEMA‐Na without ascites outperformed other scores in predicting wait‐list outcomes and may be used wherever the inclusion of ascites is considered too subjective.

23 March 2022 in Neuroscience Applied
Verified
Journal Article
Open access
ÁCÁlvaro Morcuende Campos
Álvaro Morcuende Campos
SAS. Anton
S. Anton
ENE. Nieto
E. Nieto
TFTeresa Femenía
Teresa Femenía

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
ÁCÁlvaro Morcuende Campos
Álvaro Morcuende Campos
APAndriana Perdikou
Andriana Perdikou
ENElena Nieto
Elena Nieto
SASofia Anton
Sofia Anton
TFTeresa Femenía
Teresa Femenía